PMID- 27480287
OWN - NLM
STAT- MEDLINE
DCOM- 20170926
LR  - 20181202
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 16
DP  - 2016 Aug 2
TI  - Post-crizotinib management of effective ceritinib therapy in a patient with 
      ALK-positive non-small cell lung cancer.
PG  - 568
LID - 10.1186/s12885-016-2636-z [doi]
LID - 568
AB  - BACKGROUND: We report the re-biopsied diagnosis of a patient with anaplastic 
      lymphoma receptor tyrosine kinase (ALK)-positive lung adenocarcinoma successfully 
      treated with ceritinib 450 mg/day taken with food following disease progression 
      and gastrointestinal intolerance to crizotinib. CASE PRESENTATION: A 74-year old 
      female patient initially diagnosed with ALK-negative lung adenocarcinoma 
      responded to initial standard chemotherapy. The patient was subsequently 
      re-tested by next generation sequencing (NGS) and found to have ALK EIF2AK3-ALK 
      fusion, and responded to crizotinib, but ultimately progressed and showed 
      intolerance to this ALK inhibitor. She was then successfully treated with 
      ceritinib 450 mg/day taken with food, has not suffered from any further 
      gastrointestinal side-effects, and remains on ceritinib treatment after 
      12 months. CONCLUSIONS: Second-line ceritinib treatment, when administered at 
      450 mg/day with food, is both well tolerated and efficacious in a patient with 
      previously treated lung adenocarcinoma who had discontinued crizotinib due to 
      disease progression and gastrointestinal adverse effects (AEs).
FAU - Won, Brian
AU  - Won B
AD  - Section of Hematology/Oncology, University of Chicago, 5841 South Maryland 
      Avenue, MC 2115, Chicago, IL, 60637, USA.
FAU - Mambetsariev, Isa
AU  - Mambetsariev I
AD  - Current address, Department of Medical Oncology and Therapeutics Research, City 
      of Hope, 1500 E Duarte Rd, Duarte, CA, 91010-3000, USA.
FAU - Salgia, Ravi
AU  - Salgia R
AUID- ORCID: 0000-0001-9643-7626
AD  - Current address, Department of Medical Oncology and Therapeutics Research, City 
      of Hope, 1500 E Duarte Rd, Duarte, CA, 91010-3000, USA. rsalgia@coh.org.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20160802
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Pyrazoles)
RN  - 0 (Pyridines)
RN  - 0 (Pyrimidines)
RN  - 0 (Sulfones)
RN  - 53AH36668S (Crizotinib)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.11.1 (EIF2AK3 protein, human)
RN  - EC 2.7.11.1 (eIF-2 Kinase)
RN  - K418KG2GET (ceritinib)
SB  - IM
MH  - Aged
MH  - Anaplastic Lymphoma Kinase
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics
MH  - Crizotinib
MH  - Female
MH  - Gene Fusion
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/genetics
MH  - Pyrazoles/administration & dosage/therapeutic use
MH  - Pyridines/administration & dosage/therapeutic use
MH  - Pyrimidines/*administration & dosage/therapeutic use
MH  - Receptor Protein-Tyrosine Kinases/*genetics
MH  - Sulfones/*administration & dosage/therapeutic use
MH  - Treatment Outcome
MH  - eIF-2 Kinase/*genetics
PMC - PMC4969677
OTO - NOTNLM
OT  - ALK-positive NSCLC
OT  - Case report
OT  - Ceritinib
OT  - Dose
OT  - Gastrointestinal tolerance
EDAT- 2016/08/03 06:00
MHDA- 2017/09/28 06:00
PMCR- 2016/08/02
CRDT- 2016/08/03 06:00
PHST- 2016/04/04 00:00 [received]
PHST- 2016/07/27 00:00 [accepted]
PHST- 2016/08/03 06:00 [entrez]
PHST- 2016/08/03 06:00 [pubmed]
PHST- 2017/09/28 06:00 [medline]
PHST- 2016/08/02 00:00 [pmc-release]
AID - 10.1186/s12885-016-2636-z [pii]
AID - 2636 [pii]
AID - 10.1186/s12885-016-2636-z [doi]
PST - epublish
SO  - BMC Cancer. 2016 Aug 2;16:568. doi: 10.1186/s12885-016-2636-z.